石药集团加速蜕变

米内网
Sep 28

精彩内容今年以来,石药集团喜讯不断:10个品种获批上市,10款1类新药首次获批临床,达成4项重磅BD交易等。石药集团以创新研发为发展引擎,2025年上半年研发费用达26.83亿元,占成药收入比重26.2%。目前公司有78款1类新药、19款2.2类改良新药/生物类似药在国内处于申请临床及以上阶段,其中有19款已步入NDA或III期临床,上市在即;35个新分类申报品种在审,10余个暂无首仿(含剂型首仿...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10